>Mercado de software de rastreio do cancro do pulmão no Médio Oriente e África, por modo de entrega (soluções baseadas na nuvem, soluções locais e soluções baseadas na Web), produto (solução de radiologia de rastreio do cancro do pulmão, software de gestão de doentes de rastreio de cancro do pulmão, software de gestão de nódulos, recolha de dados e relatórios, coordenação e fluxo de trabalho dos doentes, deteção assistida por computador de nódulos pulmonares, estadiamento de patologia e cancro, relatórios de auditoria estatística, PACs de rastreio , gestão de práticas e rastreio de registos de auditoria), tipo (triagem assistida por computador e triagem tradicional), aplicação ( não pequeno Cancro do Pulmão Celular (CPNPC) e Cancro do Pulmão de Pequenas Células (CPPC)), Plataforma (Autonomia e Integrada), Modalidade de Compra (Institucional e Individual), Utilizador Final (Centros de Oncologia, Hospitais, Centros Cirúrgicos Ambulatório e Outros), Canal de Distribuição (Direto Distribuidores de concursos e outsourcing) - Tendências e previsões do setor para 2029.
Análise e dimensão do mercado de software de rastreio do cancro do pulmão no Médio Oriente e África
O controlo das taxas de mortalidade por cancro do pulmão é uma das principais preocupações das unidades de saúde. As organizações públicas e privadas estão a tomar iniciativas para lançar programas de rastreio para controlar as taxas de mortalidade. Além disso, as empresas estão a lançar software avançado para facilitar a gestão dos dados dos pacientes e prestar melhores cuidados com diretrizes rigorosas de privacidade de dados.
O aumento da prevalência do cancro do pulmão, a crescente consciencialização das pessoas sobre o cancro do pulmão, o aumento das iniciativas governamentais e o número crescente de programas de rastreio são alguns dos principais factores que impulsionam o crescimento do mercado. Além disso, o avanço nas soluções baseadas em Inteligência Artificial (IA) e nas iniciativas estratégicas dos principais participantes do mercado estão a criar oportunidades na área do software de rastreio do cancro do pulmão.
No entanto, espera-se que as questões de privacidade de dados e falta de mão-de-obra não qualificada dificultem o crescimento do mercado no período de previsão.
A Data Bridge Market Research analisa que o mercado de software de rastreio do cancro do pulmão no Médio Oriente e em África deverá atingir o valor de 835,45 mil dólares até 2029, com um CAGR de 14,9% durante o período de previsão . As soluções baseadas na cloud são responsáveis pelo maior segmento de modo de entrega do mercado. O relatório de mercado abrange também análises de preços, análises de patentes e avanços tecnológicos em profundidade.
|
Métrica de relatório |
Detalhes |
|
Período de previsão |
2022 a 2029 |
|
Ano base |
2021 |
|
Anos históricos |
2020 (personalizável para 2019-2014) |
|
Unidades Quantitativas |
Receita em milhares de dólares, preço em dólares |
|
Segmentos cobertos |
By Mode of Delivery (Cloud Based Solutions, On-Premise Solutions and Web Based Solutions), Product (Lung Cancer Screening Radiology Solution, Lung Cancer Screening Patient Management Software, Nodule Management Software, Data Collection and Reporting, Patient Coordination and Workflow, Lung Nodule Computer Aided Detection, Pathology and Cancer Staging, Statistical Audit Reporting, Screening PACs, Practice Management and Audit Log Tracking), Type (Computer-Assisted Screening and Traditional Screening), Application (Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)), Platform (Standalone and Integrated), Purchase Mode (Institutional and Individual), End User (Oncology Centers, Hospitals, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender and Third Party Distributors) |
|
Countries Covered |
U.A.E., Saudi Arabia, Israel, Egypt, South Africa, and rest of Middle East and Africa |
|
Market Players Covered |
PenRad Technologies Inc., Koninklijke Philips N.V, Volpara Health Limited, Thynk Health, Nuance Communications, Inc., Siemens Healthcare GmbH, MyCareWare, Inc., MagView, MeVis Medical Solutions AG, Canon Medical Informatics, Inc., General Electric Company, Epic Systems Corporation, Lungview, Eon, Medtronic, Coreline Soft Co., Ltd., Optellum Ltd, HealthMyne, Oncocyte Corporation, Genesystem, REVEALDX, FUJIFILM Holdings Corporation, F. Hoffmann-La Roche Ltd, Median Technologies, AstraZeneca, and Aidence.com |
Market Definition
Lung cancer screening is identifying stages of lung cancer using different technologies and software. Lung cancer screening using CT is the most recommended technique for screening lung cancer. The rising use of this technique is expected to accelerate the need for advanced software for lung cancer screening. This software helps to manage patients’ participation in lung screening programs and provides an efficient way for healthcare professionals to collect, curate, and transfer data to clinicians and patients. In addition, this software enables in the identification of patients at risk and automates the flow of data with integrated electronic health records.
Middle East and Africa Lung Cancer Screening Software Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increase in prevalence of lung cancer cases globally
Lung cancer is a leading cause of death in men and women. According to World Cancer Research Fund International, lung cancer is the second most common cancer worldwide. It is the most common cancer in men and second most common in women. There were more than 2.2 thousand new cases of lung cancer in 2020. Increasing prevalence of lung cancer cases creates need to adopt lung cancer screening software for early diagnosis and acts as a driving factor for the market growth.
- Increase in awareness regarding the benefits of early diagnosis and frequent screening
Prevê-se que os crescentes programas de sensibilização para o cancro do pulmão por parte de organizações públicas, sem fins lucrativos e privadas impulsionem o crescimento do mercado. Estas iniciativas visam prevenir doenças, reduzir o estigma e o preconceito e promover a investigação. A consciencialização da população sobre o cancro do pulmão tem aumentado. Como existem muitos programas de sensibilização realizados por diferentes organizações, as pessoas sabem que o cancro do pulmão pode ser curado se for diagnosticado precocemente. Assim, a sensibilização das populações está a impulsionar o crescimento do mercado.
- Foram empreendidas iniciativas governamentais para implementar programas de rastreio de diversas doenças
O fardo do cancro continua a aumentar a nível mundial e provoca um grande stress financeiro, emocional e físico nos sistemas de saúde, nos produtos, nas famílias e nos indivíduos. Em países com sistemas de saúde fortes, a taxa de sobrevivência de muitos tipos de cancro melhora devido à sobrevivência, aos cuidados de qualidade, ao aumento da sensibilização e à detecção precoce acessível. Os Centros de Controlo e Prevenção de Doenças, os EUA, as tribos e as ilhas e territórios dos EUA-Pacífico, através do Programa Nacional Abrangente de Controlo do Cancro (NCCCP), devem formar ou apoiar alianças para combater o cancro nas suas comunidades . Com estas iniciativas, mais públicos são educados e mais conscientemente dispersos, incentivando o público global a ter mais cuidados e a praticar exames preventivos, promovendo o mercado.
- Número crescente de programas de rastreio em todo o mundo
O rastreio é um método eficaz para detetar o cancro numa fase inicial. Existe uma tendência crescente na incidência de cancro do pulmão nos países em desenvolvimento. Embora existam recomendações regulares para o rastreio do cancro da mama e do colo do útero, o mesmo não acontece no caso do cancro do pulmão. A maioria dos países ou instituições iniciou a viabilidade e o rastreio de doenças através da tomografia computorizada de baixa dose (LDCT) para o cancro do pulmão. O número crescente de rastreios de cancro do pulmão criou uma oportunidade para os participantes do mercado. Assim, a crescente taxa de diagnóstico atua como um fator impulsionador para o crescimento do mercado.
Oportunidade
-
Aumento das colaborações, fusões e aquisições entre os participantes do mercado
As empresas que operam no mercado estão a adotar diversas estratégias, incluindo fusões e aquisições, lançamentos de produtos, acordos, desenvolvimento de pipeline, colaborações e expansão de mercados, entre outras, para impulsionar os seus negócios em diversas dimensões. Espera-se que estas decisões estratégicas das empresas ofereçam oportunidades significativas para os players do mercado que operam no mercado.
Restrições/Desafios
- Problemas relacionados com a disponibilidade de software
Existem certas questões/barreiras relacionadas com o rastreio eficaz e eficiente do cancro do pulmão e a disponibilidade de software de rastreio do cancro do pulmão nos países em desenvolvimento. Os problemas são exigências concorrentes de tempo, conhecimento sobre o rastreio do cancro do pulmão, evolução das atitudes sobre a eficácia do rastreio, niilismo relacionado com resultados historicamente fracos do tratamento do cancro do pulmão e formação limitada e aprovação de requisitos para as autoridades locais ou para o organismo regulador de dispositivos médicos do país. Todas estas questões atrasam o lançamento e a disponibilidade do produto. Além disso, a procura de software de rastreio do cancro do pulmão é prejudicada devido a questões técnicas relacionadas com o software disponível, atuando assim como uma restrição ao crescimento do mercado.
Impacto pós-COVID-19 no mercado de software de rastreio do cancro do pulmão no Médio Oriente e em África
A COVID-19 criou um grande impacto em várias indústrias, uma vez que quase todos os países optaram pelo encerramento de todas as instalações, exceto as que lidam com o segmento dos bens essenciais. O governo tomou algumas medidas rigorosas, como o encerramento de instalações e a venda de bens não essenciais, o bloqueio do comércio internacional e muitas outras para impedir a propagação da COVID-19. O único negócio que funcionou durante esta situação de pandemia foram os serviços essenciais que puderam abrir e gerir os processos.
A COVID-19 criou novos e desconhecidos desafios para os prestadores de cuidados de saúde prestarem cuidados aos doentes. Muitos serviços não essenciais, mas importantes, como o rastreio do cancro do pulmão, foram temporariamente suspensos para proteger a saúde dos funcionários e dos doentes. As instituições de saúde enfrentaram desafios sem precedentes em termos de agendamento, monitorização dos doentes e acompanhamento da comunicação doente-serviço para garantir a continuidade dos cuidados durante a COVID-19 e quando os serviços pudessem ser continuados em segurança. A COVID-19 criou novos desafios para os programas de rastreio do cancro do pulmão, em muitos casos, atrasando o rastreio por vários meses e criando mais dificuldades para as equipas de gestão e agendamento. Embora a crise da COVID-19 tenha lançado uma nova luz sobre a importância da assistência respiratória, espera-se que tenha um grande impacto na redução do estigma do rastreio do cancro. Existem mais de 10 milhões de doentes elegíveis nos EUA que são elegíveis para rastreio do cancro do pulmão, menos de 5 por cento dos quais estão activamente inscritos no programa de rastreio. O COVID-19 criou um impacto negativo no mercado.
No entanto, as empresas de software de rastreio do cancro do pulmão estão a lutar e a tomar continuamente diferentes decisões estratégicas para controlar a situação. Os players estão envolvidos em atividades estratégicas como parcerias, colaborações e fusões e aquisições, entre outras, para melhorar a tecnologia envolvida no mercado. Com isto, as empresas trarão para o mercado soluções avançadas e precisas. Além disso, as iniciativas governamentais para impulsionar a digitalização em todas as indústrias também levaram ao crescimento do mercado.
Desenvolvimentos recentes
- Em julho de 2022, a GE Healthcare lançou o seu mais recente produto e ultrassons mais avançados, o Voluson Expert 22 de próxima geração. Esta última adição ao premiado portefólio de Saúde da Mulher da GE Healthcare utiliza tecnologia de formação de feixe baseada em gráficos, que produz imagens de maior qualidade e oferece maior flexibilidade nas funções de imagem. Com este produto, a empresa reforçou ainda mais a sua posição na área da prestação de produtos e serviços a instituições de saúde.
- Em outubro de 2021, a Thynk Health anunciou uma parceria com a Infervision, para combater o cancro do pulmão com as tecnologias mais avançadas do mundo. Oferece uma oportunidade para o rastreio do cancro do pulmão e tratamento de nódulos pulmonares. Com esta parceria, a empresa aumentou a sua presença no mercado.
Âmbito do mercado de software de rastreio do cancro do pulmão no Médio Oriente e África
O mercado de software de rastreio do cancro do pulmão no Médio Oriente e em África está segmentado em oito segmentos notáveis com base no modo de entrega, produto, tipo, aplicação, plataforma, modo de compra, utilizador final e canal de distribuição. O crescimento entre estes segmentos irá ajudá-lo a analisar segmentos de crescimento escasso nas indústrias e fornecer aos utilizadores uma valiosa visão geral do mercado e insights de mercado para os ajudar a tomar decisões estratégicas para identificar as principais aplicações do mercado.
Modo de entrega
- Soluções baseadas na nuvem
- Soluções locais
- Soluções baseadas na Web
Com base no modo de entrega, o mercado está segmentado em soluções baseadas na cloud, soluções locais e soluções baseadas na web.
Produto
- Solução de radiologia para rastreio de cancro de pulmão
- Software de gestão de doentes para rastreio de cancro de pulmão
- Software de gestão de nódulos
- Recolha de dados e relatórios
- Coordenação do doente e fluxo de trabalho
- Detecção assistida por computador de nódulo pulmonar
- Patologia e estadiamento do cancro
- Relatórios de auditoria estatística
- Triagem PACS
- Gestão Prática
- Acompanhamento de registo de auditoria
Com base no produto, o mercado está segmentado em solução de radiologia de rastreio do cancro do pulmão, software de gestão de doentes para rastreio do cancro do pulmão, software de gestão de nódulos, recolha e relatórios de dados, coordenação e fluxo de trabalho de doentes, deteção assistida por computador de nódulos pulmonares, patologia e estadiamento do cancro, relatórios de auditoria estatística, rastreio de PACS, gestão de práticas e rastreio de registos de auditoria.
Tipo
- Triagem assistida por computador
- Triagem Tradicional
Com base no tipo, o mercado está segmentado em triagem assistida por computador e triagem tradicional.
Aplicação
Com base na aplicação, o mercado está segmentado em Cancro do Pulmão de Células Não Pequenas (NSCLC) e Cancro do Pulmão de Pequenas Células (SCLC).
Plataforma
- Autônomo
- Integrado
Com base na plataforma, o mercado está segmentado em autónomo e integrado.
Modo de compra
- Institucional
- Individual
Com base na modalidade de compra, o mercado está segmentado em individual e institucional.
Utilizador final
- Centros de Oncologia
- Hospitais
- Centros Cirúrgicos Ambulatoriais
- Outros
On the basis of end user, the market is segmented into hospitals, oncology centers, ambulatory surgical centers, and others.
Distribution Channel
- Direct Tender
- Third Party Distributors
On the basis of distribution channel, the market is segmented into direct tender and third party distributors.
Middle East and Africa Lung Cancer Screening Software Market Regional Analysis/Insights
Middle East and Africa market is analyzed and market size insights and trends are provided based on mode of delivery, product, type, application, platform, purchase mode, end user, and distribution channel as referenced above.
The countries covered in this market report are U.A.E., Saudi Arabia, Israel, Egypt, South Africa, and rest of Middle East and Africa. Saudi Arabia dominates the market owing to factors such as, on-going strategic partnerships and the presence of major key players in the region. Moreover, some underdeveloped countries in this region do not have access to technological services in the healthcare sector which has led to the region slow growth in the market.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Lung Cancer Screening Software Market Share Analysis
Middle East and Africa lung cancer screening software market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the market are PenRad Technologies Inc., Koninklijke Philips N.V, Volpara Health Limited, Thynk Health, Nuance Communications, Inc., Siemens Healthcare GmBH, MyCareWare, Inc., MagView, MeVis Medical Solutions AG, Canon Medical Informatics, Inc., General Electric Company, Epic Systems Corporation, Lungview, Eon, Medtronic, Coreline Soft, Co., Ltd., Optellum Ltd, HealthMyne, Oncocyte Corporation, Genesystem, REVEALDX, FUJIFILM Holdings Corporation, F. Hoffmann-La Roche Ltd, Median Technologies, AstraZeneca, and Aidence.com among others.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET
1.4 LIMITATION
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 REGULATIONS & REIMBURSEMENT
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASE IN PREVALENCE OF LUNG CANCER CASES MIDDLE EAST & AFRICALY
6.1.2 INCREASE IN AWARENESS REGARDING THE BENEFITS OF EARLY DIAGNOSIS AND FREQUENT SCREENING
6.1.3 GOVERNMENT INITIATIVES WERE UNDERTAKEN TO IMPLEMENT SCREENING PROGRAMS FOR VARIOUS DISEASES
6.1.4 GROWING NUMBER OF SCREENING PROGRAMS ACROSS THE GLOBE
6.1.5 TECHNOLOGICAL ADVANCEMENTS IN THE FIELD OF HEALTHCARE
6.2 RESTRAINTS
6.2.1 ISSUES RELATED TO THE AVAILABILITY OF SOFTWARE
6.2.2 SCARCITY OF TECHNICALLY KNOWLEDGEABLE PROFESSIONALS FOR CANCER DIAGNOSIS
6.2.3 LACK OF FUNDING AND OTHER RESOURCES FROM VARIOUS REGIONS FOR CANCER AND ASSOCIATED DISORDERS
6.3 OPPORTUNITIES
6.3.1 RISING COLLABORATIONS, MERGERS & ACQUISITIONS AMONG THE MARKET PLAYERS
6.3.2 INCREASING INVESTMENTS IN HEALTHCARE SEGMENTS
6.3.3 MULTIPLE BENEFITS ASSOCIATED WITH LUNG CANCER SCREENING SOFTWARE
6.4 CHALLENGES
6.4.1 HIGH COST OF SCREENING SOFTWARE AND RELATED SERVICES
6.4.2 INCREASING CHALLENGES RELATED TO THE DEVELOPMENT OF LUNG CANCER SCREENING SOFTWARE
6.4.3 INCREASING COMPETITION IN THE MARKET
7 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY
7.1 OVERVIEW
7.2 CLOUD BASED SOLUTIONS
7.3 ON-PREMISE SOLUTIONS
7.4 WEB BASED SOLUTIONS
8 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 LUNG CANCER SCREENING RADIOLOGY SOLUTION
8.2.1 ON-PREMISE SOLUTIONS
8.2.2 WEB BASED SOLUTIONS
8.2.3 CLOUD BASED SOLUTIONS
8.3 LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE
8.3.1 CLOUD BASED SOLUTIONS
8.3.2 ON-PREMISE SOLUTIONS
8.3.3 WEB BASED SOLUTIONS
8.4 NODULE MANAGEMENT SOFTWARE
8.4.1 CLOUD BASED SOLUTIONS
8.4.2 ON-PREMISE SOLUTIONS
8.4.3 WEB BASED SOLUTIONS
8.5 DATA COLLECTION AND REPORTING
8.5.1 CLOUD BASED SOLUTIONS
8.5.2 WEB BASED SOLUTIONS
8.5.3 ON-PREMISE SOLUTIONS
8.6 PATIENT COORDINATION AND WORKFLOW
8.6.1 CLOUD BASED SOLUTIONS
8.6.2 ON-PREMISE SOLUTIONS
8.6.3 WEB BASED SOLUTIONS
8.7 LUNG NODULE COMPUTER AIDED DETECTION
8.7.1 ON-PREMISE SOLUTIONS
8.7.2 CLOUD BASED SOLUTIONS
8.7.3 WEB BASED SOLUTIONS
8.8 PATHOLOGY AND CANCER STAGING
8.8.1 CLOUD BASED SOLUTIONS
8.8.2 ON-PREMISE SOLUTIONS
8.8.3 WEB BASED SOLUTIONS
8.9 STATISTICAL AUDIT REPORTING
8.9.1 CLOUD BASED SOLUTIONS
8.9.2 ON-PREMISE SOLUTIONS
8.9.3 WEB BASED SOLUTIONS
8.1 SCREENING PACS
8.10.1 CLOUD BASED SOLUTIONS
8.10.2 ON-PREMISE SOLUTIONS
8.10.3 WEB BASED SOLUTIONS
8.11 PRACTICE MANAGEMENT
8.11.1 CLOUD BASED SOLUTIONS
8.11.2 ON-PREMISE SOLUTIONS
8.11.3 WEB BASED SOLUTIONS
8.12 AUDIT LOG TRACKING
8.12.1 CLOUD BASED SOLUTIONS
8.12.2 ON-PREMISE SOLUTIONS
8.12.3 WEB BASED SOLUTIONS
9 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE
9.1 OVERVIEW
9.2 COMPUTER-ASSISTED SCREENING
9.2.1 CLOUD BASED SOLUTIONS
9.2.2 ON-PREMISE SOLUTIONS
9.2.3 WEB BASED SOLUTIONS
9.3 TRADITIONAL SCREENING
9.3.1 CLOUD BASED SOLUTIONS
9.3.2 ON-PREMISE SOLUTIONS
9.3.3 WEB BASED SOLUTIONS
10 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 NON-SMALL CELL LUNG CANCER (NSCLC)
10.2.1 CLOUD BASED SOLUTIONS
10.2.2 ON-PREMISE SOLUTIONS
10.2.3 WEB BASED SOLUTIONS
10.3 SMALL CELL LUNG CANCER (SCLC)
10.3.1 CLOUD BASED SOLUTIONS
10.3.2 ON-PREMISE SOLUTIONS
10.3.3 WEB BASED SOLUTIONS
11 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM
11.1 OVERVIEW
11.2 STANDALONE
11.2.1 CLOUD BASED SOLUTIONS
11.2.2 ON-PREMISE SOLUTIONS
11.2.3 WEB BASED SOLUTIONS
11.3 INTEGRATED
11.3.1 CLOUD BASED SOLUTIONS
11.3.2 ON-PREMISE SOLUTIONS
11.3.3 WEB BASED SOLUTIONS
12 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE
12.1 OVERVIEW
12.2 INSTITUTIONAL
12.3 INDIVIDUAL
13 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER
13.1 OVERVIEW
13.2 ONCOLOGY CENTERS
13.3 HOSPITALS
13.4 AMBULATORY SURGICAL CENTERS
13.5 OTHERS
14 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDERS
14.3 THIRD PARTY DISTRIBUTOR
15 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION
15.1 MIDDLE EAST & AFRICA
15.1.1 SOUTH AFRICA
15.1.2 SOUTH AFRICA
15.1.3 U.A.E
15.1.4 ISRAEL
15.1.5 EGYPT
15.1.6 REST OF MIDDLE EAST AND AFRICA
16 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 KONINKLIJKE PHILIPS N.V
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 SIEMENS HEALTHCARE GMBH
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 NUANCE COMMUNICATIONS, INC.
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 GENRAL ELECTRIC (GE HEALTHCARE)
18.4.1 COMPANY SNAPSHOT
18.4.2 COMPANY SHARE ANALYSIS
18.4.3 PRODUCT PORTFOLIO
18.4.4 RECENT DEVELOPMENTS
18.5 ONCOCYTE CORPORATION
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENT
18.6 AIDENCE.COM
18.6.1 COMPANY SNAPSHOT
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.7 ASTRAZENECA
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 CANON MEDICAL INFORMATICS, INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENTS
18.9 CORELINE SOFT, CO., LTD.
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENTS
18.1 EON
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 EPIC SYSTEMS CORPORATION
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.12 F. HOFFMANN-LA ROCHE LTD
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENTS
18.13 FUJIFILM HOLDINGS CORPORATION
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 GENESYSTEM
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENT
18.15 HEALTHMYNE
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENTS
18.16 LUNGVIEW
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENT
18.17 MAGVIEW
18.17.1 COMPANY SNAPSHOT
18.17.2 PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENT
18.18 MEDIAN TECHNOLOGIES
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENT
18.19 MEDTRONIC
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 PRODUCT PORTFOLIO
18.19.4 RECENT DEVELOPMENTS
18.2 MEVIS MEDICAL SOLUTIONS AG
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENT
18.21 MYCAREWARE INC.
18.21.1 COMPANY SNAPSHOT
18.21.2 PRODUCT PORTFOLIO
18.21.3 RECENT DEVELOPMENT
18.22 OPTELLUM LTD
18.22.1 COMPANY SNAPSHOT
18.22.2 PRODUCT PORTFOLIO
18.22.3 RECENT DEVELOPMENTS
18.23 PENRAD TECHNOLOGIES INC.
18.23.1 COMPANY SNAPSHOT
18.23.2 PRODUCT PORTFOLIO
18.23.3 RECENT DEVELOPMENT
18.24 REVEALDX
18.24.1 COMPANY SNAPSHOT
18.24.2 PRODUCT PORTFOLIO
18.24.3 RECENT DEVELOPMENT
18.25 THYNK HEALTH
18.25.1 COMPANY SNAPSHOT
18.25.2 PRODUCT PORTFOLIO
18.25.3 RECENT DEVELOPMENT
18.26 VOLPARA SOLUTIONS LIMITED
18.26.1 COMPANY SNAPSHOT
18.26.2 REVENUE ANALYSIS
18.26.3 PRODUCT PORTFOLIO
18.26.4 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
Lista de Tabela
TABLE 1 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)
TABLE 2 MIDDLE EAST & AFRICA CLOUD BASED SOLUTIONS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 3 MIDDLE EAST & AFRICA ON-PREMISE SOLUTIONS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 4 MIDDLE EAST & AFRICA WEB BASED SOLUTIONS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 5 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 6 MIDDLE EAST & AFRICA LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 7 MIDDLE EAST & AFRICA LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 8 MIDDLE EAST & AFRICA LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 9 MIDDLE EAST & AFRICA LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 10 MIDDLE EAST & AFRICA NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 11 MIDDLE EAST & AFRICA NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 12 MIDDLE EAST & AFRICA DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 13 MIDDLE EAST & AFRICA DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 14 MIDDLE EAST & AFRICA PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 15 MIDDLE EAST & AFRICA PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 16 MIDDLE EAST & AFRICA LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 17 MIDDLE EAST & AFRICA LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 18 MIDDLE EAST & AFRICA PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 19 MIDDLE EAST & AFRICA PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 20 MIDDLE EAST & AFRICA STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 21 MIDDLE EAST & AFRICA STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 22 MIDDLE EAST & AFRICA SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 23 MIDDLE EAST & AFRICA SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 24 MIDDLE EAST & AFRICA PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 25 MIDDLE EAST & AFRICA PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 26 MIDDLE EAST & AFRICA AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 27 MIDDLE EAST & AFRICA AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 28 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 29 MIDDLE EAST & AFRICA COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 30 MIDDLE EAST & AFRICA COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 31 MIDDLE EAST & AFRICA TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 32 MIDDLE EAST & AFRICA TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 33 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 34 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 35 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 36 MIDDLE EAST & AFRICA SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 37 MIDDLE EAST & AFRICA SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 38 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)
TABLE 39 MIDDLE EAST & AFRICA STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 40 MIDDLE EAST & AFRICA STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 41 MIDDLE EAST & AFRICA INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 42 MIDDLE EAST & AFRICA INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 43 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)
TABLE 44 MIDDLE EAST & AFRICA INSTITUTIONAL IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 45 MIDDLE EAST & AFRICA INDIVIDUAL IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 46 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 47 MIDDLE EAST & AFRICA ONCOLOGY CENTERS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 48 MIDDLE EAST & AFRICA HOSPITALS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 49 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 50 MIDDLE EAST & AFRICA OTHERS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 51 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 52 MIDDLE EAST & AFRICA DIRECT TENDERS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 53 MIDDLE EAST & AFRICA THIRD PARTY DISTRIBUTOR IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 54 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)
TABLE 55 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)
TABLE 56 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 57 MIDDLE EAST & AFRICA LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 58 MIDDLE EAST & AFRICA LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 59 MIDDLE EAST & AFRICA NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 60 MIDDLE EAST & AFRICA DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 61 MIDDLE EAST & AFRICA PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 62 MIDDLE EAST & AFRICA LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 63 MIDDLE EAST & AFRICA PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 64 MIDDLE EAST & AFRICA STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 65 MIDDLE EAST & AFRICA SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 66 MIDDLE EAST & AFRICA PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 67 MIDDLE EAST & AFRICA AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 68 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 69 MIDDLE EAST & AFRICA COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 70 MIDDLE EAST & AFRICA TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 71 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 72 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)
TABLE 73 MIDDLE EAST & AFRICA SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 74 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)
TABLE 75 MIDDLE EAST & AFRICA STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)
TABLE 76 MIDDLE EAST & AFRICA INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)
TABLE 77 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)
TABLE 78 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 79 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 80 SAUDI ARABIA LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)
TABLE 81 SAUDI ARABIA LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 82 SAUDI ARABIA LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 83 SAUDI ARABIA LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 84 SAUDI ARABIA NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 85 SAUDI ARABIA DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 86 SAUDI ARABIA PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 87 SAUDI ARABIA LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 88 SAUDI ARABIA PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 89 SAUDI ARABIA STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 90 SAUDI ARABIA SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 91 SAUDI ARABIA PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 92 SAUDI ARABIA AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 93 SAUDI ARABIA LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 94 SAUDI ARABIA COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 95 SAUDI ARABIA TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 96 SAUDI ARABIA LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 97 SAUDI ARABIA NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)
TABLE 98 SAUDI ARABIA SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 99 SAUDI ARABIA LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)
TABLE 100 SAUDI ARABIA STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)
TABLE 101 SAUDI ARABIA INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)
TABLE 102 SAUDI ARABIA LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)
TABLE 103 SAUDI ARABIA LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 104 SAUDI ARABIA LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 105 SOUTH AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)
TABLE 106 SOUTH AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 107 SOUTH AFRICA LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 108 SOUTH AFRICA LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 109 SOUTH AFRICA NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 110 SOUTH AFRICA DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 111 SOUTH AFRICA PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 112 SOUTH AFRICA LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 113 SOUTH AFRICA PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 114 SOUTH AFRICA STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 115 SOUTH AFRICA SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 116 SOUTH AFRICA PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 117 SOUTH AFRICA AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 118 SOUTH AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 119 SOUTH AFRICA COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 120 SOUTH AFRICA TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 121 SOUTH AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 122 SOUTH AFRICA NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)
TABLE 123 SOUTH AFRICA SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 124 SOUTH AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)
TABLE 125 SOUTH AFRICA STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)
TABLE 126 SOUTH AFRICA INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)
TABLE 127 SOUTH AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)
TABLE 128 SOUTH AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 129 SOUTH AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 130 U.A.E LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)
TABLE 131 U.A.E LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 132 U.A.E LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 133 U.A.E LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 134 U.A.E NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 135 U.A.E DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 136 U.A.E PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 137 U.A.E LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 138 U.A.E PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 139 U.A.E STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 140 U.A.E SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 141 U.A.E PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 142 U.A.E AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 143 U.A.E LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 144 U.A.E COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 145 U.A.E TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 146 U.A.E LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 147 U.A.E NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)
TABLE 148 U.A.E SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 149 U.A.E LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)
TABLE 150 U.A.E STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)
TABLE 151 U.A.E INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)
TABLE 152 U.A.E LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)
TABLE 153 U.A.E LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 154 U.A.E LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 155 ISRAEL LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)
TABLE 156 ISRAEL LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 157 ISRAEL LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 158 ISRAEL LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 159 ISRAEL NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 160 ISRAEL DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 161 ISRAEL PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 162 ISRAEL LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 163 ISRAEL PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 164 ISRAEL STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 165 ISRAEL SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 166 ISRAEL PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 167 ISRAEL AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 168 ISRAEL LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 169 ISRAEL COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 170 ISRAEL TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 171 ISRAEL LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 172 ISRAEL NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)
TABLE 173 ISRAEL SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 174 ISRAEL LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)
TABLE 175 ISRAEL STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)
TABLE 176 ISRAEL INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)
TABLE 177 ISRAEL LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)
TABLE 178 ISRAEL LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 179 ISRAEL LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 180 EGYPT LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)
TABLE 181 EGYPT LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 182 EGYPT LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 183 EGYPT LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 184 EGYPT NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 185 EGYPT DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 186 EGYPT PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 187 EGYPT LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 188 EGYPT PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 189 EGYPT STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 190 EGYPT SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 191 EGYPT PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 192 EGYPT AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 193 EGYPT LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 194 EGYPT COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 195 EGYPT TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 196 EGYPT LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 197 EGYPT NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)
TABLE 198 EGYPT SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 199 EGYPT LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)
TABLE 200 EGYPT STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)
TABLE 201 EGYPT INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)
TABLE 202 EGYPT LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)
TABLE 203 EGYPT LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 204 EGYPT LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 205 REST OF MIDDLE EAST AND AFRICA LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)
Lista de Figura
FIGURE 1 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: SEGMENTATION
FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 11 RISING LUNG CANCER SCREENING PROGRAMS IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 CLOUD BASED SOLUTIONS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET
FIGURE 14 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY MODE OF DELIVERY, 2021
FIGURE 15 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY PRODUCT, 2021
FIGURE 16 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: TYPE, 2021
FIGURE 17 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY APPLICATION, 2021
FIGURE 18 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY PLATFORM, 2021
FIGURE 19 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY PURCHASE MODE, 2021
FIGURE 20 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY END USER, 2021
FIGURE 21 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 22 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: SNAPSHOT (2021)
FIGURE 23 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY COUNTRY (2021)
FIGURE 24 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY COUNTRY (2022 & 2029)
FIGURE 25 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY COUNTRY (2021 & 2029)
FIGURE 26 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: BY MODE OF DELIVERY (2022-2029)
FIGURE 27 MIDDLE EAST & AFRICA LUNG CANCER SCREENING SOFTWARE MARKET: COMPANY SHARE 2021 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
